Analysis of a case of oxaliplatin - induced persistence sensory neuropathy
Matsuo, K.; Higuchi, M.; Sasaki, Y.; Iwatsubo, S.; Wada, Y.; Hasegawa, K.; Shirakawa, A.; Mishima, K.; Iwasaki, K.; Fujiwara, M.; Nishino, H.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(3): 551-554
2010
ISSN/ISBN: 0385-0684 PMID: 20332703 Document Number: 643225
Thirty-seven patients with advanced or recurrent colorectal cancer were treated with mFOLFOX6 or mFOLFOX6 with a Bevacizumab regimen between September 2008 and March 2009. Then, we evaluated persistent neuropathy using the National Cancer Institute Common Terminology Criteria for Adverse Events (ver. 3). As a result of the research, grade 1-3 sensory neuropathy was observed in 5.6% after 3 cycles, 44. 4% after 5 cycles, 83. 3% after 8 cycles, and 83. 4% after 10 cycles. The average dose of L-OHP (mg/m2) until persistent sensory neuropathy appeared was grade 1: 399.7+/-157. 0 (17/ 37 patients); grade 2: 418.0+/-214. 1 (5/37 patients); and grade 3: 498.0+/-152. 8 (3/37 patients). As has been shown in international clinical trials, the severity and frequency of L-OHP-induced neurotoxicity are associated with the cumulative dose and duration of L-OHP administration. Further research is necessary to develop strategies for preventing or treating this side effect.